We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

160 hedge funds and large institutions have $1.78B invested in Syndax Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

28% more capital invested

Capital invested by funds: $1.39B → $1.78B (+$393M)

15% more funds holding

Funds holding: 139 → 160 (+21)

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

8% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $2.56M

0.59% more ownership

Funds ownership: 105.87% → 106.47% (+0.59%)

Holders
160
Holders Change
+21
Holders Change %
+15.11%
% of All Funds
2.57%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.18%
New
32
Increased
65
Reduced
41
Closed
10
Calls
$2.77M
Puts
$2.56M
Net Calls
+$203K
Net Calls Change
-$4.79M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$83.9M
2
State Street
State Street
Massachusetts
+$24M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$21.5M
4
PBA
Paradigm Biocapital Advisors
New York
+$20.3M
5
Barclays
Barclays
United Kingdom
+$16M

Top Sellers

1
WP
Woodline Partners
California
-$19M
2
HM
HealthCor Management
New York
-$18.4M
3
6CM
683 Capital Management
New York
-$13.1M
4
NCM
Nantahala Capital Management
Connecticut
-$9.32M
5
BI
BVF Inc
California
-$8.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$203M +$83.9M +3,596,002 +82%
APM
2
Avidity Partners Management
Texas
$149M +$6.39M +274,100 +5%
BlackRock
3
BlackRock
New York
$111M +$4.95M +212,415 +5%
FLSM
4
Frazier Life Sciences Management
California
$94.4M +$6.9M +296,000 +9%
State Street
5
State Street
Massachusetts
$92.9M +$24M +1,031,026 +39%
Vanguard Group
6
Vanguard Group
Pennsylvania
$85.6M +$13.1M +561,151 +20%
ACA
7
Avoro Capital Advisors
New York
$67.4M +$9.98M +427,778 +19%
KCM
8
Kynam Capital Management
New Jersey
$65.2M +$6.72M +288,272 +13%
Jennison Associates
9
Jennison Associates
New York
$58.6M +$15.2M +652,451 +40%
O
10
OrbiMed
New York
$51.1M – – –
PBA
11
Paradigm Biocapital Advisors
New York
$49.7M +$20.3M +869,370 +80%
PHS
12
PFM Health Sciences
California
$46.2M +$12.3M +525,561 +41%
Citadel Advisors
13
Citadel Advisors
Florida
$41.4M +$6.09M +261,082 +19%
EP
14
Eversept Partners
New York
$41.2M +$9.55M +409,279 +34%
BI
15
BVF Inc
California
$36.9M -$8.09M -346,888 -19%
B
16
Braidwell
Connecticut
$31.6M +$29M +1,242,802 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$28M +$3.1M +132,900 +14%
ACM
18
Aisling Capital Management
New York
$26.1M – – –
T. Rowe Price Investment Management
19
T. Rowe Price Investment Management
Maryland
$25.5M +$1.86M +79,660 +9%
NCM
20
Nantahala Capital Management
Connecticut
$24.8M -$9.32M -399,723 -29%
Barclays
21
Barclays
United Kingdom
$24.5M +$16M +687,577 +249%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$23.9M -$7.23M -310,000 -25%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$23.5M +$21.5M +923,400 New
FCMI
24
Foresite Capital Management IV
California
$22.3M +$4.31M +185,000 +27%
SFM
25
Sphera Funds Management
Israel
$18.1M -$2.62M -112,135 -14%
1
2 3 4 5

SNDX Hedge Fund Activity: Q4 2022 in Review

160 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2022, worth a combined $1.78B — up 28% from $1.39B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SNDX positions and 10 closed out — a net gain of 22 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $83.9M. The largest seller was Woodline Partners, exiting entirely with an estimated $19M sold.

  • 160 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2022, up from 139 in Q3 2022.
  • Funds reported $1.78B of Syndax Pharmaceuticals stock for Q4 2022, up 28% quarter-over-quarter.
  • 32 funds opened new Syndax Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +22 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2022 was Wellington Management Group, an estimated $83.9M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2022 was Woodline Partners, an estimated $19M sold.

Based on aggregated 13F filings for Q4 2022.